Identifying ED patients with previous abnormal HIV or hepatitis C test results who may require additional services

被引:2
|
作者
Ruffner, Andrew H. [1 ]
Ancona, Rachel M. [1 ]
Hamilton, Catherine [2 ]
Fernandez, Francisco J. [1 ]
Faryar, Kiran A. [1 ]
Lane, Bennett H. [1 ]
Lyons, Michael S. [1 ]
机构
[1] Univ Cincinnati, Dept Emergency Med, Coll Med, Med Sci Bldg Room 1654,231 Albert Sabin Way, Cincinnati, OH 45267 USA
[2] Univ Cincinnati Hlth, 3200 Burnet Ave, Cincinnati, OH 45229 USA
来源
关键词
HIV; HCV; Health services; Emergency department;
D O I
10.1016/j.ajem.2020.05.020
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: Routine emergency department (ED) HIV or HCV screening may inadvertently capture patients already diagnosed but does not specifically prioritize identification of this group. Our objective was to preliminarily estimate the volume of this distinct group in our ED population through a pilot electronic health record (EHR) build that identified all patients with indications of HIV or HCV in their EHR at time of ED presentation. Methods: Cross-sectional study of an urban, academic ED's HIV/HCV program for previously diagnosed patients August 2017-July 2018. Prevention program staff, alerted by the EHR, reviewed records and interviewed patients to determine if confirmatory testing or linkage to care was needed. Primary outcome was total proportion of ED patients for whom the EHR generated an alert. Secondary outcome was the proportion of patients assessed by program staff who required confirmatory testing or linkage to HIV/HCV medical care. Results: There were 65,374 ED encounters with 5238 (8.0%, 95% CI: 7.8%-8.2%) EHR alerts. Of these, 3741 were assessed by program staff, with 798 (21%, 95% CI: 20%-23%) requiring HIV/HCV confirmatory testing or linkage to care services, 163 (20%) for HIV, 551 (69%) for HCV, and 84 (11%) for both HIV and HCV services. Conclusions: Patients with existing indication of HIV or HCV infection in need of confirmatory testing or linkage to care were common in this ED. EDs should prioritize identifying this population, outside of routine screening, and intervene similarly regardless of whether the patient is newly or previously diagnosed. (c) 2020 Published by Elsevier Inc.
引用
收藏
页码:1831 / 1833
页数:3
相关论文
共 10 条
  • [1] Deep sequencing shows that HIV patients co-infected with acute hepatitis C harbour additional viruses that may cause hepatitis
    Devine, K.
    Harder, L.
    Al Otaibi, S.
    Abdelrahman, T.
    Klymenko, T.
    Main, J.
    Thomson, E.
    [J]. HIV MEDICINE, 2014, 15 : 139 - 139
  • [2] Physicians more frequently test for HIV in patients with chronic hepatitis C who have a history of intravenous drug use
    Ali, Raziuddin
    Agrawal, Jay
    Borum, Marie
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S149 - S150
  • [3] Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results
    Lacombe, Karine
    Valin, Nadia
    Stitou, Hind
    Gozlan, Joel
    Thibault, Vincent
    Boyd, Anders
    Poirier, Jean-Marie
    Meynard, Jean-Luc
    Valantin, Marc-Antoine
    Bottero, Julie
    Girard, Pierre-Marie
    [J]. AIDS, 2013, 27 (08) : 1356 - 1359
  • [4] Daily interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C patients who have relaped or not responded to previous treatment: One year treatment results.
    Karasu, Z
    Gurakar, AO
    Jazzar, AS
    Emmett, C
    McMillon, GC
    Nour, BM
    Wright, HI
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A1455 - A1455
  • [5] Daily use of consensus interferon for chronic hepatitis C among patients who had relapsed or not responded to previous treatment with alpha interferon 2b: One year treatment results.
    Karasu, Z
    Gurakar, AO
    Jazzar, AS
    Emmett, C
    Hulagu, S
    Balkan, M
    Nour, BM
    Wright, HI
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A1455 - A1455
  • [6] Peginterferon α-2a (40 kda) plus ribavirin in chronic hepatitis C patients who failed previous interferon-based therapy:: Results of a multicentre open-label expanded access program in Canada
    Sherman, M
    Yoshida, E
    Deschenes, M
    Krajden, M
    Bain, V
    Peltekian, K
    Anderson, E
    Kaita, K
    Simonyi, S
    Lee, S
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 : 220 - 220
  • [7] THE NON INVASIVE 13C METHACETIN BREATH TEST ACCURATELY PREDICTS LONG TERM SURVIVAL IN PATIENTS WITH CHRONIC VIRAL HEPATITIS AND MAY SERVE AS AN ADJUNCTIVE TOOL TO MELD: RESULTS OF A 395 PATIENT CLINICAL TRIAL
    Lalazar, Gadi
    Mullhaupt, Beat
    Adar, Tomer
    Goetze, Oliver
    Mizrahi, Meir
    Safadi, Rifaat
    Zigmond, Ehud
    Hemed, Nilla
    Ilan, Yaron
    [J]. HEPATOLOGY, 2009, 50 (04) : 349A - 349A
  • [8] A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3-Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate
    Rivero-Juarez, Antonio
    Lopez-Cortes, Luis F.
    Camacho, Angela
    Mira, Jose A.
    Tellez, Francisco
    Marquez, Manuel
    Merino, Dolores
    Pineda, Juan A.
    Rivero, Antonio
    [J]. CLINICAL INFECTIOUS DISEASES, 2014, 58 (01) : 130 - 133
  • [9] The target trial:: Final results using 3.0μg/kg pegylated interferon alfa 2-b (Peg;Peg-intron®) plus ribavirin (RBV;rebetol®) for chronic hepatitis C patients who were non-responders (NR) and relapsers (R) to previous therapy.
    White, C
    Wentworth, C
    Malet, P
    Lee, W
    Cantu, V
    Orellana, M
    Strauss, R
    [J]. HEPATOLOGY, 2005, 42 (04) : 651A - 651A
  • [10] Similar rates of HCV recurrence in HCV/HIV co-infected and HCV mono-infected patients who achieved SVR after DAA treatment: interim results from the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).
    Wyles, David L.
    Kang, Minhee
    Matining, Roy
    Murphy, Robert
    Peters, Marion G.
    [J]. HEPATOLOGY, 2017, 66 : 523A - 524A